EUVIMEDScopri EUVIMED
Crossref

Anticancer Properties of Hexosamine Analogs Designed to Attenuate Metabolic Flux through the Hexosamine Biosynthetic Pathway

Christopher T Saeui, Sagar R Shah, Beatriz I Fernandez-Gil iD, Cissy Zhang, Christian Agatemor, Kris Dammen-Brower iD, Mohit P Mathew, Matthew Buettner, Prateek Gowda iD, Pratik Khare, Andrea Otamendi-Lopez, Shuang Yang iD and 4 more

ACS Chemical Biology · 2023

DOI: 10.1021/acschembio.2c00784 ↗

At a glance

Journal article in ACS Chemical Biology, 2023. Written by Christopher T Saeui and 15 co-authors. Institution: Department of Biomedical Engineering and The Translational Tissue Engineering Center, The Johns Hopkins University and Johns Hopkins School of Medici…. Major MEDLINE topics: Pancreatic Neoplasms, Antineoplastic Agents. Cited 9 times so far (Crossref); 90 references. Funded by: National Cancer Institute, Florida Department of State, National Heart, Lung, and Blood Institute.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Altered cellular metabolism is a hallmark of cancer pathogenesis and progression; for example, a near-universal feature of cancer is increased metabolic flux through the hexosamine biosynthetic pathway (HBP). This pathway produces uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), a potent oncometabolite that drives multiple facets of cancer progression. In this study, we synthesized and evaluated peracetylated hexosamine analogs designed to reduce flux through the HBP. By screening a panel of analogs in pancreatic cancer and glioblastoma multiform (GBM) cells, we identified Ac4Glc2Bz─a benzyl-modified GlcNAc mimetic─as an antiproliferative cancer drug candidate that down-regulated oncogenic metabolites and reduced GBM cell motility at concentrations non-toxic to non-neoplastic cells. More specifically, the growth inhibitory effects of Ac4Glc2Bz were linked to reduced levels of UDP-GlcNAc and concomitant decreases in protein O-GlcNAc modification in both pancreatic cancer and GBM cells. Targeted metabolomics analysis in GBM cells showed that Ac4Glc2Bz disturbed glucose metabolism, amino acid pools, and nucleotide precursor biosynthesis, consistent with reduced proliferation and other anti-oncogenic properties of this analog. Furthermore, Ac4Glc2Bz reduced the invasion, migration, and stemness of GBM cells. Importantly, normal metabolic functions mediated by UDP-GlcNAc were not disrupted in non-neoplastic cells, including maintenance of endogenous levels of O-GlcNAcylation with no global disruption of N-glycan production. Finally, a pilot in vivo study showed that a potential therapeutic window exists where animals tolerated 5- to 10-fold higher levels of Ac4Glc2Bz than projected for in vivo efficacy. Together, these results establish GlcNAc analogs targeting the HBP through salvage mechanisms as a new therapeutic approach to safely normalize an important facet of aberrant glucose metabolism associated with cancer.

Subjects

MeSH terms (MEDLINE)

Pancreatic NeoplasmsAntineoplastic AgentsAnimalsBiosynthetic PathwaysHexosaminesGlucoseUridine DiphosphateAcetylglucosamine

Substances

HexosaminesAntineoplastic AgentsGlucoseUridine DiphosphateAcetylglucosamine

Authors and institutions

  • Department of Biomedical Engineering and The Translational Tissue Engineering Center, The Johns Hopkins University and Johns Hopkins School of Medicine, Baltimore, Maryland 21231, United States.
  • Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida 32224, United States.
  • Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States.
  • Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland 21205, United States.
  • Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, United States.

ORCID profiles: Beatriz I Fernandez-Gil, Kris Dammen-Brower, Prateek Gowda, Shuang Yang, Hui Zhang, Kevin J Yarema

Funding

  • National Cancer Institute
  • Florida Department of State
  • National Heart, Lung, and Blood Institute
  • Office of the Director
  • Mayo Clinic
  • University of Florida
  • Florida Center for Tumor Research
  • Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine

Cite

APA

Saeui, C. T., Shah, S. R., Fernandez-Gil, B. I., Zhang, C., Agatemor, C., Dammen-Brower, K., Mathew, M. P., Buettner, M., Gowda, P., Khare, P., Otamendi-Lopez, A., Yang, S., Zhang, H., Le, A., Quinoñes-Hinojosa, A., & Yarema, K. J. (2023). Anticancer Properties of Hexosamine Analogs Designed to Attenuate Metabolic Flux through the Hexosamine Biosynthetic Pathway. ACS Chemical Biology. https://doi.org/10.1021/acschembio.2c00784

Vancouver

Saeui CT, Shah SR, Fernandez-Gil BI, Zhang C, Agatemor C, Dammen-Brower K, et al. Anticancer Properties of Hexosamine Analogs Designed to Attenuate Metabolic Flux through the Hexosamine Biosynthetic Pathway. ACS Chemical Biology. 2023. doi:10.1021/acschembio.2c00784

BibTeX
@article{Saeui2023,
  author = {Saeui, Christopher T and Shah, Sagar R and Fernandez-Gil, Beatriz I and Zhang, Cissy and Agatemor, Christian and Dammen-Brower, Kris and Mathew, Mohit P and Buettner, Matthew and Gowda, Prateek and Khare, Pratik and Otamendi-Lopez, Andrea and Yang, Shuang and Zhang, Hui and Le, Anne and Quinoñes-Hinojosa, Alfredo and Yarema, Kevin J},
  title = {Anticancer Properties of Hexosamine Analogs Designed to Attenuate Metabolic Flux through the Hexosamine Biosynthetic Pathway},
  journal = {ACS Chemical Biology},
  year = {2023},
  doi = {10.1021/acschembio.2c00784}
}
Start for free →